ENTERED


#2 OIPE

RAW SEQUENCE LISTING DATE: 01/10/2002 PATENT APPLICATION: US/09/965,099 TIME: 09:26:42

Input Set : N:\Crf3\RULE60\09965099.txt
Output Set: N:\CRF3\01102002\1965099.raw

## SEQUENCE LISTING

```
3 (1) GENERAL INFORMATION:
               (i) APPLICANT: Blackburn, Michael
       6
                              Feuerstein, Giora
       7
                              Patel, Arunbhai
              (ii) TITLE OF INVENTION: ANTICOAGULANT AGENTS USEFUL IN
       9
      10
                                        TREATMENT OF THROMBOSIS
      12
             (iii) NUMBER OF SEQUENCES: 111
      14
              (iv) CORRESPONDENCE ADDRESS:
      15
                    (A) ADDRESSEE: SmithKline Beecham Corporation
      16
                    (B) STREET: 709 Swedeland Road
      17
                    (C) CITY: King of Prussia
      18
                    (D) STATE: PA
      19
                    (E) COUNTRY: USA
      20
                    (F) ZIP: 19406
      22
              (V) COMPUTER READABLE FORM:
      23
                    (A) MEDIUM TYPE: Diskette
      24
                    (B) COMPUTER: IBM Compatible
      25
                   (C) OPERATING SYSTEM: DOS
      26
                   (D) SOFTWARE: FastSEQ Version 1.5
      28
             (vi) CURRENT APPLICATION DATA:
 C--> 29
                   (A) APPLICATION NUMBER: US/09/965,099
 C--> 30
                   (B) FILING DATE: 26-Sep-2001
      31
                   (C) CLASSIFICATION:
      33
            (vii) PRIOR APPLICATION DATA:
      34
                   (A) APPLICATION NUMBER: 09/346,487
      35
                   (B) FILING DATE:
     39
           (viii) ATTORNEY/AGENT INFORMATION:
     40
                   (A) NAME: Baumeister, Kirk
     41
                   (B) REGISTRATION NUMBER: 33,833
     42
                   (C) REFERENCE/DOCKET NUMBER: P50438-1
     44
             (ix) TELECOMMUNICATION INFORMATION:
     45
                   (A) TELEPHONE: 610-270-5096
     46
                   (B) TELEFAX:
     47
                   (C) TELEX:
     50
        (2) INFORMATION FOR SEQ ID NO: 1:
     52
              (i) SEQUENCE CHARACTERISTICS:
     53
                   (A) LENGTH: 20 base pairs
     54
                   (B) TYPE: nucleic acid
     55
                   (C) STRANDEDNESS: single
     56
                   (D) TOPOLOGY: linear
     58
            (ii) MOLECULE TYPE: cDNA
     59
           (iii) HYPOTHETICAL: NO
     60
            (iv) ANTI-SENSE: NO
W--> 61
             (V) FRAGMENT TYPE:
     62
            (vi) ORIGINAL SOURCE:
     64
            (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
```



PATENT APPLICATION: US/09/965,099

DATE: 01/10/2002 TIME: 09:26:42

Input Set : N:\Crf3\RULE60\09965099.txt
Output Set: N:\CRF3\01102002\1965099.raw

```
CATCCTAGAG TCACCGAGGA
                                                                                    20
      68 (2) INFORMATION FOR SEQ ID NO: 2:
               (i) SEQUENCE CHARACTERISTICS:
      71
                    (A) LENGTH: 21 base pairs
      72
                    (B) TYPE: nucleic acid
      73
                    (C) STRANDEDNESS: single
      74
                    (D) TOPOLOGY: linear
      76
             (ii) MOLECULE TYPE: cDNA
      77
            (iii) HYPOTHETICAL: NO
             (iv) ANTI-SENSE: NO
      78
 W--> 79
              (V) FRAGMENT TYPE:
      80
             (vi) ORIGINAL SOURCE:
      82
             (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
          AGCTGCCCAA AGTGCCCAAG C
      84
                                                                                   21
         (2) INFORMATION FOR SEQ ID NO: 3:
      88
              (i) SEQUENCE CHARACTERISTICS:
      89
                   (A) LENGTH: 36 base pairs
      90
                   (B) TYPE: nucleic acid
      91
                   (C) STRANDEDNESS: single
      92
                   (D) TOPOLOGY: linear
             (ii) MOLECULE TYPE: cDNA
     95
            (iii) HYPOTHETICAL: NO
     96
             (iv) ANTI-SENSE: NO
₩--> 97
              (V) FRAGMENT TYPE:
     98
             (vi) ORIGINAL SOURCE:
     100
              (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
     102
          CTAACACTCA TTCCTGTTGA AGCTCTTGAC AATGGG
     104 (2) INFORMATION FOR SEQ ID NO: 4:
                                                                                    36
     106
              (i) SEQUENCE CHARACTERISTICS:
     107
                    (A) LENGTH: 21 base pairs
     108
                    (B) TYPE: nucleic acid
     109
                   (C) STRANDEDNESS: single
     110
                   (D) TOPOLOGY: linear
     112
             (ii) MOLECULE TYPE: cDNA
     113
            (iii) HYPOTHETICAL: NO
     114
             (iv) ANTI-SENSE: NO
W--> 115
              (V) FRAGMENT TYPE:
     116
             (vi) ORIGINAL SOURCE:
    118
             (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
         GATTTTCARG TGCAGATTTT C
                                                                                   21
    122 (2) INFORMATION FOR SEQ ID NO: 5:
    124
              (i) SEQUENCE CHARACTERISTICS:
    125
                   (A) LENGTH: 363 base pairs
    126
                   (B) TYPE: nucleic acid
    127
                   (C) STRANDEDNESS: single
    128
                   (D) TOPOLOGY: linear
    130
             (ii) MOLECULE TYPE: cDNA
    131
            (iii) HYPOTHETICAL: NO
    132
            (iv) ANTI-SENSE: NO
```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/965,099

DATE: 01/10/2002 TIME: 09:26:42

Input Set : N:\Crf3\RULE60\09965099.txt
Output Set: N:\CRF3\01102002\I965099.raw

W:	> 133		( v	) FF	RAGME	NT I	YPE:											
	134		(vi	.) OF	RIGIN	AL S	OURC	E:										
		136 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: 138 CAGATCCAGT TGGTGCAGTC TGGACCTGAG CTGAAGAGC CTGCAGAGAGA AGTGAAGAAGA																
	138														(2) ) (2) ===			
	139		CICC	nnoo	CII	CIGG	GTA	CACC	TTTCA	CA A	ል ርጥ አ	ጥርርአ	7 mc	' A A CIT	CCCE			60
	139 TCCTGCAAGG CTTCTGGGTA CACCTTCACA AACTATGGAA TGAACTGGGT GAAGC 140 CCAGGAAAGG GTTTAAAGTG GATGGCTTG ATAAACACCA GAAATGGAAA GTCAA 141 GTTGATGACT TCAAGGGACG GTTTGCCTTC TCTTTGGAAA GCTCTGCCAG CACTG 142 TTGCAGATCG ACAACCTCAA AGATGAGAGA ACGGCTACAT ATTTCTGTAC AAGAG												<b>λ</b> Γλ	120				
													maa	180				
	142		00110	$\alpha + c c$	ACH	MUCI	CAA	A(JA'I	( - A ( - ( -	ΔΥ Δ	cccc	ጠ አ ፖ አ	m 2 m		~~~			240
	143	AA	TATG	GATG	GTT	ACTT	CCC	TTTT	ACTT	AC T	GGGG	CCDD	G GG	A CTC	TCCTT TCCTT	CAG	AGAAGGG TGTCTCT	300
		00										001111	0 00	ACIC	1661	CAC	TGTCTCT	360
	146 (2) INFORMATION FOR SEQ ID NO: 6: 148 (i) SEQUENCE CHARACTERISTICS:															363		
	148		(i	) SE	QUEN	CE C	HARA	CTER	ISTI	CS:								
	149			()	A) L	ENGT	H: 3	21 b	ase	pair	S							
	150			(1	B) T	YPE:	nuc.	leic	aci	d								
	150 (B) TYPE: nucleic acid 151 (C) STRANDEDNESS: single																	
	152 (D) TOPOLOGY: linear																	
	154		(ii)	MOI	LECUI	LE TY	YPE:	CDN	A									
	155	1	(iii)	HYI	POTHE	ETICA	AL: 1	O										
	156				CI-SE													
M>			( V )	FR2	GMEN	T TY	PE:											
	158				GINA													
	160		(xi)	SEÇ	QUENC	E DE	SCR	PTIC	ON: S	SEQ 1	D NO	): 6:						
	162	CAA	ATT	TTC	TCTC	CCAC	TC T	CCAC	CAAT	C CT	יכיייטיי	יכר א יו	• СПС	CAGG	CCA	CAAC	GTCACA	<i>c</i> 0
	163		111CI 1	CA	GGGC	CAGC	TCP	AGTO	HAAL	עדיידי∧	ለሮል ጥር	ירא כית	י ככו	77 007	CON	0330		60 120
	164		-1000	CCA	MACC	CIGG	AT I	TATO	CCAC	'A TIC	'ר'א א ר	יכיייככ		CMCC	12 CM	000		180
	165			CA	GIGG	GICI	ن جات	ACCI	.'CT"TA	C TC	יייירייירי	ממיז בו	ריים יים	CCAC	יא כיוח	0030	CCDC-	240
		165 TTCAGTGGCA GTGGGTCTGG GACCTCTTAC TCTCTCACAA TCAGCAGAGT GGAGGCTGAA 166 GATGCTGCCA CTTATTACTG CCAGCAGTGG AGTATTAACC CACGGACGTT CGGTGGAGGC												300				
	167 ACCAAGCTGG AAATCAAACG G 169 (2) INFORMATION FOR SEQ ID NO: 7: 171 (i) SEQUENCE CHARACTERISTICS: 172 (A) LENGTH: 121 amino acids 173 (B) TYPE: amino acid 174 (C) STRANDEDNESS: single 175 (D) TOPOLOGY: linear												321					
													321					
	177		/::\	(D	) TO	POLO	GY:	line	ar									
	178	,	( <del></del> )	MOT	ECUL	E TY	PE:	pept	ide									
	179	(		ANIM	OTHE	PICA.	L: N	0										
	180				I-SE				_									
	181		( V ) ( <del>171</del> 1 )	ODT	GMEN'	r ry.	PE:	inte	rnal									
	183		(VI) /Vi)	CEO	GINA:	- 50i	JRCE	:	_									
		Gln	Tle	Gla	JENCI	Mal	CI-	PTIO.	N: S	EQ II	ON C	: 7:						
	185 186	1		OIN	шец	vaı 5	GIII	ser	GIY	Pro	Glu	Leu	Lys	Lys	Pro	Gly	Glu	
	187		Val	Lvs	Tla	Sar	Crra	T	31.	<u> </u>	10	_				15		
	188			_,	Ile 20	261	Cys	гуѕ	Ата	ser	GIY	Tyr	Thr	Phe		Asn	$\mathtt{Tyr}$	
		Glv	Met	Asn		٧a٦	Lara	C1-	7.7 -	25	-1	_			30			
	190	1		35	Trp	val	пЛг	GIN	ATA	Pro	GLY	Lys	Gly		Lys	Trp	Met	
		Glv	Trp		Asn	ጥb r	Δτα	λας	40	T	<b>G</b> = -	m)		45				
	L92	1	50		Asn	T 11T	AT 9	Asn 55	стА	гàг	ser	Thr	Tyr	Val	Asp	Asp	Phe	
													£ (A)					
-	L93	Lys	Gly	Arq	Phe	Ala	Phe	Ser	Leu	Gl.	Cc~	C	60					

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/965,099

DATE: 01/10/2002
TIME: 09:26:42

Input Set : N:\Crf3\RULE60\09965099.txt
Output Set: N:\CRF3\01102002\I965099.raw

```
194 65
  195 Leu Gln Ile Asp Asn Leu Lys Asp Glu Asp Thr Ala Thr Tyr Phe Cys
                                                 75
  196
                                             90
       Thr Arg Glu Gly Asn Met Asp Gly Tyr Phe Pro Phe Thr Tyr Trp Gly
  197
  198
                                         105
       Gln Gly Thr Leu Val Thr Val Ser Ala
  199
  200
               115
  202 (2) INFORMATION FOR SEQ ID NO: 8:
  204
           (i) SEQUENCE CHARACTERISTICS:
  205
                (A) LENGTH: 5 amino acids
  206
                (B) TYPE: amino acid
  207
                (C) STRANDEDNESS: single
  208
                (D) TOPOLOGY: linear
  210
          (ii) MOLECULE TYPE: peptide
  211
         (iii) HYPOTHETICAL: NO
  212
          (iv) ANTI-SENSE: NO
  213
           (v) FRAGMENT TYPE: internal
  214
          (vi) ORIGINAL SOURCE:
          (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
  216
  218
      Asn Tyr Gly Met Asn
 219
       1
 221 (2) INFORMATION FOR SEQ ID NO: 9:
 223
          (i) SEQUENCE CHARACTERISTICS:
 224
               (A) LENGTH: 17 amino acids
 225
               (B) TYPE: amino acid
 226
               (C) STRANDEDNESS: single
 227
               (D) TOPOLOGY: linear
 229
         (ii) MOLECULE TYPE: peptide
 230
        (iii) HYPOTHETICAL: NO
 231
         (iv) ANTI-SENSE: NO
 232
          (V) FRAGMENT TYPE: internal
 233
         (vi) ORIGINAL SOURCE:
         (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
 235
     Trp Ile Asn Thr Arg Asn Gly Lys Ser Thr Tyr Val Asp Asp Phe Lys
 237
238
239 Gly
242 (2) INFORMATION FOR SEQ ID NO: 10:
         (i) SEQUENCE CHARACTERISTICS:
245
               (A) LENGTH: 12 amino acids
246
              (B) TYPE: amino acid
247
              (C) STRANDEDNESS: single
248
              (D) TOPOLOGY: linear
250
       (ii) MOLECULE TYPE: peptide
251
       (iii) HYPOTHETICAL: NO
252
        (iv) ANTI-SENSE: NO
253
         (V) FRAGMENT TYPE: internal
254
        (vi) ORIGINAL SOURCE:
256
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
    Glu Gly Asn Met Asp Gly Tyr Phe Pro Phe Thr Tyr
258
```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/965,099

DATE: 01/10/2002 TIME: 09:26:42

Input Set : N:\Crf3\RULE60\09965099.txt
Output Set: N:\CRF3\01102002\I965099.raw

```
259
         1
   261 (2) INFORMATION FOR SEQ ID NO: 11:
            (i) SEQUENCE CHARACTERISTICS:
   264
                 (A) LENGTH: 107 amino acids
   265
                 (B) TYPE: amino acid
   266
                 (C) STRANDEDNESS: single
   267
                 (D) TOPOLOGY: linear
           (ii) MOLECULE TYPE: peptide
   269
   270
          (iii) HYPOTHETICAL: NO
   271
           (iv) ANTI-SENSE: NO
  272
           (v) FRAGMENT TYPE: internal
  273
           (vi) ORIGINAL SOURCE:
          (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
  275
       Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly
  277
  278
       Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Asn Tyr Met
  279
  280
       His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr
                                        25
  281
  282
      Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser
  283
  284
      Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu
  285
  286
      Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ile Asn Pro Arg Thr
 287
 288
      Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg
 289
 290
                   100
 292 (2) INFORMATION FOR SEQ ID NO: 12:
 294
          (i) SEQUENCE CHARACTERISTICS:
 295
               (A) LENGTH: 10 amino acids
 296
               (B) TYPE: amino acid
 297
               (C) STRANDEDNESS: single
 298
               (D) TOPOLOGY: linear
 300
         (ii) MOLECULE TYPE: peptide
301
        (iii) HYPOTHETICAL: NO
302
         (iv) ANTI-SENSE: NO
303
         (V) FRAGMENT TYPE: internal
304
         (vi) ORIGINAL SOURCE:
306
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
     Arg Ala Ser Ser Ser Val Asn Tyr Met His
308
309
                       5
311 (2) INFORMATION FOR SEQ ID NO: 13:
         (i) SEQUENCE CHARACTERISTICS:
314
              (A) LENGTH: 7 amino acids
315
              (B) TYPE: amino acid
316
              (C) STRANDEDNESS: single
317
              (D) TOPOLOGY: linear
319
        (ii) MOLECULE TYPE: peptide
320
       (iii) HYPOTHETICAL: NO
```




DATE: 01/10/2002

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/965,099

Input Set: N:\Crf3\RULE60\09965099.txt
Output Set: N:\CRF3\01102002\1965099.raw

L:29 M:220 C: Keyword misspelled or invalid format, [(A) APPLICATION NUMBER:] L:30 M:220 C: Keyword misspelled or invalid format, [(B) FILING DATE:] L:61 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=1 L:79 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=2 L:97 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=3 L:115 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=4 L:133 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=5 L:157 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=6 L:360 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=15 L:379 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=16 L:398 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=17 L:417 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=18 L:436 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=19 L:518 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=21 L:536 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=22 L:554 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=23 L:606 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=25 L:625 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=26 L:643 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=27 L:661 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=28
L:680 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=29 L:699 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=30 L:786 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=32 L:806 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=33 L:826 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=34 L:901 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=36 L:919 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=37 L:937 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=38 L:988 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=40 L:1006 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=41 L:1024 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=42 L:1042 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=43 L:1123 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=45 L:1143 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=46 L:1163 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=47 L:1232 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=49 L:1250 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=50 L:1268 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=51 L:1355 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=53 L:1374 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=54 L:1414 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=56 L:1495 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=58 L:1513 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=59 L:1550 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=61 L:1631 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=63 L:1651 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=64 L:1671 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=65 L:1746 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=67



PATENT APPLICATION: US/09/965,099

DATE: 01/10/2002 TIME: 09:26:43

Input Set : N:\Crf3\RULE60\09965099.txt
Output Set: N:\CRF3\01102002\1965099.raw

L:1764 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=68 L:1820 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=69 L:1838 M:246 W: Invalid value of Alpha Sequence Header Field, [FRAGMENT TYPE:], SeqNo=71 SeqNo=72